These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16403056)

  • 21. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure.
    Ghali JK; Boehmer J; Feldman AM; Saxon LA; Demarco T; Carson P; Yong P; Galle EG; Leigh J; Ecklund FL; Bristow MR
    J Card Fail; 2007 Nov; 13(9):769-73. PubMed ID: 17996827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of the multicenter RENEWAL 3 AVT clinical study of cardiac resynchronization defibrillator therapy in patients with paroxysmal atrial fibrillation.
    Saxon LA; Greenfield RA; Crandall BG; Nydegger CC; Orlov M; VAN Genderen R
    J Cardiovasc Electrophysiol; 2006 May; 17(5):520-5. PubMed ID: 16684026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of right ventricular lead location on response to cardiac resynchronization therapy in patients with end-stage heart failure.
    Haghjoo M; Bonakdar HR; Jorat MV; Fazelifar AF; Alizadeh A; Ojaghi-Haghjghi Z; Esmaielzadeh M; Sadr-Ameli MA
    Europace; 2009 Mar; 11(3):356-63. PubMed ID: 19136489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in heart rate variability, quality of life, and activity in cardiac resynchronization therapy patients: results of the HF-HRV registry.
    Gilliam FR; Kaplan AJ; Black J; Chase KJ; Mullin CM
    Pacing Clin Electrophysiol; 2007 Jan; 30(1):56-64. PubMed ID: 17241316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.
    Daubert C; Gold MR; Abraham WT; Ghio S; Hassager C; Goode G; Szili-Török T; Linde C;
    J Am Coll Cardiol; 2009 Nov; 54(20):1837-46. PubMed ID: 19800193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triple-site biventricular pacing in patients undergoing cardiac resynchronization therapy: a feasibility study.
    Lenarczyk R; Kowalski O; Kukulski T; Szulik M; Pruszkowska-Skrzep P; Zielinska T; Kowalczyk J; Pluta S; Duszanska A; Sredniawa B; Musialik-Lydka A; Kalarus Z
    Europace; 2007 Sep; 9(9):762-7. PubMed ID: 17631515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High defibrillation threshold in patients with implantable defibrillator: how effective is the subcutaneous finger lead?
    Osswald BR; De Simone R; Most S; Tochtermann U; Tanzeem A; Karck M
    Eur J Cardiothorac Surg; 2009 Mar; 35(3):489-92. PubMed ID: 19144533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiac contractility modulation in non-responders to cardiac resynchronization therapy.
    Nägele H; Behrens S; Eisermann C
    Europace; 2008 Dec; 10(12):1375-80. PubMed ID: 18776196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of biventricular pacing using a totally endocardial approach in patients with end-stage cardiac failure.
    Pasquié JL; Massin F; Macia JC; Gervasoni R; Bortone A; Cayla G; Grolleau R; Leclercq F
    Pacing Clin Electrophysiol; 2007 Jan; 30 Suppl 1():S31-3. PubMed ID: 17302712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the effects of cardiac resynchronization therapy in patients with class II versus class III and IV heart failure (from the InSync/InSync ICD Italian Registry).
    Landolina M; Lunati M; Gasparini M; Santini M; Padeletti L; Achilli A; Bianchi S; Laurenzi F; Curnis A; Vincenti A; Valsecchi S; Denaro A;
    Am J Cardiol; 2007 Sep; 100(6):1007-12. PubMed ID: 17826388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial.
    Saxon LA; Bristow MR; Boehmer J; Krueger S; Kass DA; De Marco T; Carson P; DiCarlo L; Feldman AM; Galle E; Ecklund F
    Circulation; 2006 Dec; 114(25):2766-72. PubMed ID: 17159063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delayed defibrillation testing after CRT-D implant-weighing competing risks.
    Saxon L
    J Cardiovasc Electrophysiol; 2005 Dec; 16(12):1284-5. PubMed ID: 16403057
    [No Abstract]   [Full Text] [Related]  

  • 34. Twenty-millisecond interventricular difference as assessed by body surface potential mapping identifies patients with clinical improvement after implantation of cardiac resynchronization device.
    Samesima N; Douglas R; Tobias N; Pedrosa A; Martinelli Filho M; Ramires JA; Pastore CA
    Anadolu Kardiyol Derg; 2007 Jul; 7 Suppl 1():213-5. PubMed ID: 17584728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Remission of left ventricular systolic dysfunction and of heart failure symptoms after cardiac resynchronization therapy: temporal pattern and clinical predictors.
    Gasparini M; Regoli F; Ceriotti C; Galimberti P; Bragato R; De Vita S; Pini D; Andreuzzi B; Mangiavacchi M; Klersy C
    Am Heart J; 2008 Mar; 155(3):507-14. PubMed ID: 18294488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The benefits of biventricular pacing in heart failure patients with narrow QRS, NYHA class II and right ventricular pacing.
    Ng K; Kedia N; Martin D; Tchou P; Natale A; Wilkoff B; Starling R; Grimm RA
    Pacing Clin Electrophysiol; 2007 Feb; 30(2):193-8. PubMed ID: 17338715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study.
    De Marco T; Wolfel E; Feldman AM; Lowes B; Higginbotham MB; Ghali JK; Wagoner L; Kirlin PC; Kennett JD; Goel S; Saxon LA; Boehmer JP; Mann D; Galle E; Ecklund F; Yong P; Bristow MR
    J Card Fail; 2008 Feb; 14(1):9-18. PubMed ID: 18226768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical evaluation of defibrillation testing in an unselected population of 2,120 consecutive patients undergoing first implantable cardioverter-defibrillator implant.
    Brignole M; Occhetta E; Bongiorni MG; Proclemer A; Favale S; Iacopino S; Calò L; Vado A; Buja G; Mascioli G; Quartieri F; Tritto M; Parravicini U; Castro A; Tomasi C; Villani GQ; D'Acri MG; Klersy C; Gasparini M;
    J Am Coll Cardiol; 2012 Sep; 60(11):981-7. PubMed ID: 22858384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Moderate exercise training improves functional capacity, quality of life, and endothelium-dependent vasodilation in chronic heart failure patients with implantable cardioverter defibrillators and cardiac resynchronization therapy.
    Belardinelli R; Capestro F; Misiani A; Scipione P; Georgiou D
    Eur J Cardiovasc Prev Rehabil; 2006 Oct; 13(5):818-25. PubMed ID: 17001224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is implantable defibrillator indicated in all patients on cardiac resynchronization therapy?
    Pieragnoli P; Ricciardi G; Colella A; Musilli N; Porciani MC; Giaccardi M; Padeletti L; Michelucci A
    Minerva Cardioangiol; 2006 Dec; 54(6):735-41. PubMed ID: 17167385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.